Hope. When We Most Need It.
Gilead Sciences is an international company that investigates and develops drugs for incurable diseases. Since its foundation in 1987, Gilead has been investing in the development of medical breakthroughs that were considered impossible. Gilead has developed more than 25 groundbreaking drugs for diseases that were previously incurable, and by doing so contributed to changing the lives of hundreds of millions of people around the world.
Making the impossible possible – CREATING POSSIBLE – is the vision that leads us, describes our history, and reflects our commitment to a healthier and better world for everyone. Breaking barriers previously considered a reality we are bound to live with, is our driving force. This motivation is manifested in our values, and investment in programs to raise awareness of diseases, and provide accessibility to drugs for patients all around the world.
For us, at Gilead, nothing is impossible – thanks to our people, the communities in which we operate and the partners working with us. At Gilead we start every day with one question: "What next?"
Gilead's main fields of investment in drug development are HIV, COVID-19, liver diseases, oncological hematology, oncology and inflammatory diseases.
Gilead is traded on NASDAQ, and its global headquarters is located in San Francisco, USA. The company holds branches in more than 35 countries worldwide. A subsidiary of Gilead – Gilead Sciences Israel Ltd. – has been operating in Israel for 5 years.
Gilead Sciences is an international company that investigates and develops drugs for incurable diseases. Since its foundation in 1987, Gilead has been investing in the development of medical breakthroughs that were considered impossible. Gilead has developed more than 25 groundbreaking drugs for diseases that were previously incurable, and by doing so contributed to changing the lives of hundreds of millions of people around the world.
Making the impossible possible – CREATING POSSIBLE – is the vision that leads us, describes our history, and reflects our commitment to a healthier and better world for everyone. Breaking barriers previously considered a reality we are bound to live with, is our driving force. This motivation is manifested in our values, and investment in programs to raise awareness of diseases, and provide accessibility to drugs for patients all around the world.
For us, at Gilead, nothing is impossible – thanks to our people, the communities in which we operate and the partners working with us. At Gilead we start every day with one question: "What next?"
Gilead's main fields of investment in drug development are HIV, COVID-19, liver diseases, oncological hematology, oncology and inflammatory diseases.
Gilead is traded on NASDAQ, and its global headquarters is located in San Francisco, USA. The company holds branches in more than 35 countries worldwide. A subsidiary of Gilead – Gilead Sciences Israel Ltd. – has been operating in Israel for 5 years.
Gilead Sciences is an international company that investigates and develops drugs for incurable diseases. Since its foundation in 1987, Gilead has been investing in the development of medical breakthroughs that were considered impossible. Gilead has developed more than 25 groundbreaking drugs for diseases that were previously incurable, and by doing so contributed to changing the lives of hundreds of millions of people around the world.
Making the impossible possible – CREATING POSSIBLE – is the vision that leads us, describes our history, and reflects our commitment to a healthier and better world for everyone. Breaking barriers previously considered a reality we are bound to live with, is our driving force. This motivation is manifested in our values, and investment in programs to raise awareness of diseases, and provide accessibility to drugs for patients all around the world.
For us, at Gilead, nothing is impossible – thanks to our people, the communities in which we operate and the partners working with us. At Gilead we start every day with one question: "What next?"
Gilead's main fields of investment in drug development are HIV, COVID-19, liver diseases, oncological hematology, oncology and inflammatory diseases.
Gilead is traded on NASDAQ, and its global headquarters is located in San Francisco, USA. The company holds branches in more than 35 countries worldwide. A subsidiary of Gilead – Gilead Sciences Israel Ltd. – has been operating in Israel for 5 years.
Gilead Sciences is an international company that investigates and develops drugs for incurable diseases. Since its foundation in 1987, Gilead has been investing in the development of medical breakthroughs that were considered impossible. Gilead has developed more than 25 groundbreaking drugs for diseases that were previously incurable, and by doing so contributed to changing the lives of hundreds of millions of people around the world.
Making the impossible possible – CREATING POSSIBLE – is the vision that leads us, describes our history, and reflects our commitment to a healthier and better world for everyone. Breaking barriers previously considered a reality we are bound to live with, is our driving force. This motivation is manifested in our values, and investment in programs to raise awareness of diseases, and provide accessibility to drugs for patients all around the world.
For us, at Gilead, nothing is impossible – thanks to our people, the communities in which we operate and the partners working with us. At Gilead we start every day with one question: "What next?"
Gilead's main fields of investment in drug development are HIV, COVID-19, liver diseases, oncological hematology, oncology and inflammatory diseases.
Gilead is traded on NASDAQ, and its global headquarters is located in San Francisco, USA. The company holds branches in more than 35 countries worldwide. A subsidiary of Gilead – Gilead Sciences Israel Ltd. – has been operating in Israel for 5 years.
Gilead Sciences is an international company that investigates and develops drugs for incurable diseases. Since its foundation in 1987, Gilead has been investing in the development of medical breakthroughs that were considered impossible. Gilead has developed more than 25 groundbreaking drugs for diseases that were previously incurable, and by doing so contributed to changing the lives of hundreds of millions of people around the world.
Making the impossible possible – CREATING POSSIBLE – is the vision that leads us, describes our history, and reflects our commitment to a healthier and better world for everyone. Breaking barriers previously considered a reality we are bound to live with, is our driving force. This motivation is manifested in our values, and investment in programs to raise awareness of diseases, and provide accessibility to drugs for patients all around the world.
For us, at Gilead, nothing is impossible – thanks to our people, the communities in which we operate and the partners working with us. At Gilead we start every day with one question: "What next?"
Gilead's main fields of investment in drug development are HIV, COVID-19, liver diseases, oncological hematology, oncology and inflammatory diseases.
Gilead is traded on NASDAQ, and its global headquarters is located in San Francisco, USA. The company holds branches in more than 35 countries worldwide. A subsidiary of Gilead – Gilead Sciences Israel Ltd. – has been operating in Israel for 5 years.
Gilead Sciences is an international company that investigates and develops drugs for incurable diseases. Since its foundation in 1987, Gilead has been investing in the development of medical breakthroughs that were considered impossible. Gilead has developed more than 25 groundbreaking drugs for diseases that were previously incurable, and by doing so contributed to changing the lives of hundreds of millions of people around the world.
Making the impossible possible – CREATING POSSIBLE – is the vision that leads us, describes our history, and reflects our commitment to a healthier and better world for everyone. Breaking barriers previously considered a reality we are bound to live with, is our driving force. This motivation is manifested in our values, and investment in programs to raise awareness of diseases, and provide accessibility to drugs for patients all around the world.
For us, at Gilead, nothing is impossible – thanks to our people, the communities in which we operate and the partners working with us. At Gilead we start every day with one question: "What next?"
Gilead's main fields of investment in drug development are HIV, COVID-19, liver diseases, oncological hematology, oncology and inflammatory diseases.
Gilead is traded on NASDAQ, and its global headquarters is located in San Francisco, USA. The company holds branches in more than 35 countries worldwide. A subsidiary of Gilead – Gilead Sciences Israel Ltd. – has been operating in Israel for 5 years.
Gilead Sciences is an international company that investigates and develops drugs for incurable diseases. Since its foundation in 1987, Gilead has been investing in the development of medical breakthroughs that were considered impossible. Gilead has developed more than 25 groundbreaking drugs for diseases that were previously incurable, and by doing so contributed to changing the lives of hundreds of millions of people around the world.
Making the impossible possible – CREATING POSSIBLE – is the vision that leads us, describes our history, and reflects our commitment to a healthier and better world for everyone. Breaking barriers previously considered a reality we are bound to live with, is our driving force. This motivation is manifested in our values, and investment in programs to raise awareness of diseases, and provide accessibility to drugs for patients all around the world.
For us, at Gilead, nothing is impossible – thanks to our people, the communities in which we operate and the partners working with us. At Gilead we start every day with one question: "What next?"
Gilead's main fields of investment in drug development are HIV, COVID-19, liver diseases, oncological hematology, oncology and inflammatory diseases.
Gilead is traded on NASDAQ, and its global headquarters is located in San Francisco, USA. The company holds branches in more than 35 countries worldwide. A subsidiary of Gilead – Gilead Sciences Israel Ltd. – has been operating in Israel for 5 years.
Gilead Sciences is an international company that investigates and develops drugs for incurable diseases. Since its foundation in 1987, Gilead has been investing in the development of medical breakthroughs that were considered impossible. Gilead has developed more than 25 groundbreaking drugs for diseases that were previously incurable, and by doing so contributed to changing the lives of hundreds of millions of people around the world.
Making the impossible possible – CREATING POSSIBLE – is the vision that leads us, describes our history, and reflects our commitment to a healthier and better world for everyone. Breaking barriers previously considered a reality we are bound to live with, is our driving force. This motivation is manifested in our values, and investment in programs to raise awareness of diseases, and provide accessibility to drugs for patients all around the world.
For us, at Gilead, nothing is impossible – thanks to our people, the communities in which we operate and the partners working with us. At Gilead we start every day with one question: "What next?"
Gilead's main fields of investment in drug development are HIV, COVID-19, liver diseases, oncological hematology, oncology and inflammatory diseases.
Gilead is traded on NASDAQ, and its global headquarters is located in San Francisco, USA. The company holds branches in more than 35 countries worldwide. A subsidiary of Gilead – Gilead Sciences Israel Ltd. – has been operating in Israel for 5 years.
Thanks to Gilead, hepatitis C is now curable
In the past, hepatitis C was an incurable disease resulting in severe liver damage and even death, due to the development of cirrhosis. Gilead has made the impossible possible.
Gilead was the first pharmaceutical company to develop a drug for
hepatitis C and thanks to this drug more than two million people have recovered from the disease. The development of the drug marked the beginning of a global revolution, ultimately resulting in the World Health Organization setting a target of global hepatitis C eradication by the year 2030.
Today you can be cured of
Hepatitis C
For more information >>
Gilead’s innovative cancer cell therapy: CAR-T technology
Kite Pharma, who was acquired by Gilead in 2017, has developed a groundbreaking technology, named CAR-T Cell Therapy, which has changed the paradigm of cancer treatment. This technology pushed the boundaries of treatments that were offered to blood cancer patients, by using genetically modified immune cells.
CAR-T cell therapy modify the genetic cipher of T-type immune cells, allowing the genetically modified cells to target cancer cells in the patient’s body. Thanks to this innovative technology, a new horizon has been created to various cancers treatment.
Gilead has recently been working to develop innovative treatments for solid tumors.
Today it is possible to
treat Cancer
For more information >>
Gilead's message:
new quality of life for HIV positive people so they can live full lives with HIV.
In the past, people living with HIV were forced to take a cocktail of drugs consisting of approximately 30 pills each day.
Gilead has made the impossible possible. Gilead was the first company to develop HIV therapy consisting only of a single tablet per day, without compromising therapeutic efficacy.
Gilead’s HIV therapy has revolutionized the quality of life of people living with HIV and has given tens of millions across the world new options for managing the disease. Nowadays, living with HIV is as feasible as living with any other chronic disease, thanks to efficient and convenient therapy.
One Can live a full life
with HIV
For more information >>
Gilead's drug for the treatment of Corona patients
Gilead started the research and development of the drug, which was eventually approved as treatment for COVID-19 patients, many years before the Corona pandemic outbreak. The knowledge, the expertise and the commitment to the development of antiviral drugs for conditions that were considered untreatable, like Ebola and SARS, allowed Gilead to act quickly, and offer health authorities around the world a significant solution for treating COVID-19 patients.
As of December 2020, the drug manufactured by Gilead is approved for use in COVID-19 patients in approximately 50 countries, including Israel. This drug is the only therapy currently approved for COVID-19 patients in Israel.
Due to Gilead’s commitment to improving people’s quality of life and to saving human life anywhere in the world, they have granted 127 underdeveloped countries an approval to produce generic versions of the drug, alongside the drug’s approval for use in the United States. Gilead has already done this before, in many underdeveloped countries, when it approved the production of generic versions of the drugs it had developed for HIV,
hepatitis C and others.
Upon the outbreak of the global Corona pandemic, Gilead has undertaken to accelerate production, and until June 2020, has donated all of its drug stock (1.5 million doses), at no cost, for clinical trials and compassionate use around the world.
Gilead has established a uniform price for the drug for all underdeveloped countries, which is significantly lower than the value provided by the drug, with the aim of granting quick access to patients requiring treatment. This decision is another example for Gilead’s commitment and effort to respond quickly to the global need for medical answers to manage
COVID-19.
And today Corona can also
be treated
For more information >>